Precigen, Inc. (PGEN) Reports Phase 1b Study of AG019 ActoBiotics Met Primary Endpoint Assessing Safety and Tolerability

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/7/2026

1. HUVR:IN
2. ANET
3. NKE
4. PANW
5. CL
6. SNDK
7. TAP
8. DELL
9. ROIV
10. BAC

Go back to Precigen, Inc. (PGEN) Reports Phase 1b Study of AG019 ActoBiotics Met Primary Endpoint Assessing Safety and Tolerability

Precigen, Inc. (PGEN) Misses Q2 EPS by 13c, Revenues Beat

August 10, 2020 4:35 PM EDT

Precigen, Inc. (NASDAQ: PGEN) reported Q2 EPS of ($0.26), $0.13 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $30.4 million versus the consensus estimate of $13.76 million.

Second Quarter 2020 Financial Highlights:

Total revenues of $30.4 million;Net loss of $43.4... More

Precigen, Inc. (PGEN) Provides Six-month Follow-up Data from Phase I Study of INXN-4001

August 6, 2020 7:54 AM EDT

Precigen Triple-Gene, a clinical stage cardiovascular gene therapy company and majority-owned subsidiary of Precigen, Inc. (Nasdaq: PGEN), today announced six-month follow-up data from the Phase I trial of INXN-4001 (clinical trial identifier: NCT03409627), a multigenic investigational therapeutic candidate under evaluation for the treatment of heart failure.... More